Molecular analysis of residual tumors treated with MK591 revealed reduced levels of ERK, cyclin D1 and Aurora kinase B proteins, suggesting that targeting 5-Lox by MK591 or similar agents could be a potent strategy for inhibiting pancreatic tumor growth. This evidence concerns the gene AURKB and pancreatic neoplasm.